Immune cells engineered to hunt brain tumors in spinal fluid show promise in early trial
NCT ID NCT04661384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment for adults with aggressive brain cancers (glioblastoma, ependymoma, or medulloblastoma) that have spread to the lining of the brain and spinal cord. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells. The main goals are to check safety and see how long patients live. Only 10 participants are enrolled, so results are preliminary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Can the Body's own immune cells beat a recurrent brain tumor?
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?